The Global Prostate Cancer Market was worth $48 billion in 2016 and estimated to be growing at a CAGR of 9.5%, to reach $75.56 billion by 2021. The prostate cancer market has a high demand for novel drugs that concentrate on unmet needs such as improved survival time, less toxicity, better progression free survival, improved effectiveness, and lesser cost.

Prostate cancer is a progression of cancer in the prostate, a gland present in the male reproductive system. The cancer cells might reach to the other parts of the body, viz. the bones and lymph nodes from the prostate. In the later stages of cancer it can cause difficulty in urination, blood in the urine, etc. Prostate cancer is most of the times diagnosed by biopsy.

Browse market data tables and in-depth TOC of the Global Prostate Cancer Industry to 2021 @ http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/

These factors such as growing number of novel drugs expected to get launched in short-term future and rising old age male population are driving the growth of the market. Altering lifestyle, technological advancements in researching for new techniques to fight prostate cancer, increase in the funding in both public and private sector in the field of drug advancement are some of the key reasons driving the growth of the market High cost of treatment is restraining the growth of the market.

The global Prostate Cancer market is segmented on the basis of diagnostic techniques into Digital Rectal Exam (DRE) and Prostate Specific Antigen Test (PSA). Based on surgery the market is segregated into Radical Prostatectomy, Orchidectomy and Trans Urethral Resection (TUR). By radiation therapy, the market is bifurcated into External Beam Radiation Therapy and Brachytherapy.

Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/request-sample

External bean radiation therapy segment is further divided among 3D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Stereotactic Body Radiation Therapy and Proton Beam Radiation Therapy. Brachytherapy segment is sub segmented into Permanent Brachytherapy and Temporary Brachytherapy. On the basis of chemotherapy, segments are Docetaxel, Etoposide, Vinblastine, Carboplatin and Vinorelbine.

Based on geography the market is analysed under various regions namely, North America, Latin America, Europe, Asia-Pacific and Middle-East & Africa. North America region holds the largest share in the global prostate cancer market. However, Asia-Pacific and Latin America region are estimated to record the highest CAGR during the forecast period.

Inquire before Buying at http://www.marketdataforecast.com/market-reports/global-prostate-cancer-market-1616/inquire

Major companies include Sanofi S.A, GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech etc. The market registered substantial growth in the recent years, due to the various strategies such as opting for agreements and collaborations, adopted by leading market players.

About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.

Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail:[email protected]

Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/

View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases